Skip to main content

Table 3 Expression levels and fluorescence intensity of MHC and co-stimulatory molecules on the surface of 5-FU-treated cellsa, b.

From: Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice

Cell type Percentage of molecule expression, % Average fluorescence intensity
  MHC I MHC II CD80 CD86 MHC I MHC II CD80 CD86
CT-26         
Treated 92.7 ± 2.76 10.0 ± 1.56c 92.4 ± 7.85 9.2 ± 1.84c 13.6 ± 0.21c 12.5 ± 0.42d 4.3 ± 0.14c 3.5 ± 0.49c
Untreated 99.1 ± 1.27 1.5 ± 0.14 83.4 ± 6.58 3.1 ± 2.47 38.9 ± 2.34 5.0 ± 0.49 2.7 ± 0.35 1.8 ± 0.64
TC-1         
Treated 92.4 ± 2.69 1.6 ± 0.49 95.9 ± 4.03 5.3 ± 0.10c 3.0 ± 0.35c 3.6 ± 0.92c 10.7 ± 0.99c 2.9 ± 1.06
Untreated 97.5 ± 2.47 0.4 ± 0.07 95.0 ± 1.27 1.6 ± 0.49 8.2 ± 0.78 2.3 ± 0.64 5.6 ± 0.14 1.8 ± 0.71
4T-1         
Treated 69.7 ± 6.65 10.5 ± 1.13d 11.3 ± 1.27c 7.8 ± 1.27c 2.6 ± 0.49c 5.4 ± 0.49c 4.4 ± 0.85 3.5 ± 1.06
Untreated 84.4 ± 0.64 2.4 ± 1.20 2.7 ± 0.71 1.8 ± 0.07 3.8 ± 0.07 3.2 ± 0.64 2.7 ± 1.13 2.4 ± 0.92
  1. Abbreviations: MHC, major histocompatibility complex.
  2. aExperiments were repeated twice with similar results.
  3. bData are expressed as mean ± SD of the two independent experiments.
  4. c, dThe t-test was carried out to determine the difference between the two groups in three experiments: cP < 0.05, dP < 0.01, t-test).